Peptides DB
Research-centric peptide and protocol reference hub

Sermorelin record · updated 17h ago

Muscle & body compHealing & recoveryGrade B · human evidenceResearch use only
All 19 studiesJump to the evidenceCompare
What is Sermorelin used for?

Sermorelin is a synthetic peptide that mimics growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce and release endogenous growth hormone. It has been investigated for its potential therapeutic applications, particularly in the context of growth hormone deficiencies and other related conditions.

How it works: GHRH (1–29) analog

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where Sermorelin sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 52 registered trials. It describes the research record, not a recommendation.

Identity
NameSermorelin
Chain length29 amino acids
Molecular weight3,357.9 Da
FormulaC149H246N44O42S
Structure typePeptide
ClassMuscle
Research levelModerate Research
Discovered byAdded before provenance tracking · 2025

Mass and formula from PubChem CID 16132413. The chain length is only shown where the residues account for that mass, so a figure here has been checked against it rather than taken on trust.

Pharmacology
MechanismGHRH (1–29) analog
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.60
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 26, 2026. How this works →
Research stats
Total studies19
Human / animal / cellular6 / 3 / 8
Highest trial phasePreclinical
Years covered2010–2026
Latest study8d ago
Publication history
20102026
Research funding
4 NIH projects · $648k awarded · through FY2009
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports44
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

19 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Photothermal-magnetic dual-activated Janus dressing for microenvironment purification and wireless electrically triggered healing with reduced scar formation.
Finding99.37% closure of large infected full-thickness rat wounds
Animal2026Full text read0.70
Evaluation of Additional Treatment for Residual Cases After Endoscopic Papillectomy of Duodenal Ampullary Tumors.
Finding12 cases of adenocarcinoma identified, n=43.
Human2026Full text read0.80
Field-ridge structured bioactive Zn-based scaffold promotes bone regeneration via cellular mechanotransduction.
FindingNot reported in abstract.
Animal2026Full text read0.70
Diabetes-associated MYT1 and ST18 genes regulate human beta cell insulin secretion and survival via other diabetes risk genes.
FindingEnrichment of 2.05-fold relative to the random distribution of beta cell-expressed genes.
Human2026Full text read0.80
Gardnerella enrichment in the vaginal microbiome of women with gestational diabetes mellitus is associated with lower fetal birthweight percentiles.
FindingGardnerella abundance was 9.7% in GDM vs 1.4% in controls, nominal p=0.011.
Human2026Full text read0.80
Reconstituting a two-step pathway for <i>N</i>,<i>N</i>-dimethyltryptamine (DMT) biosynthesis in bacteria.
Finding103 mg/L DMT after 48 hours in complex medium.
In vitro2026Full text read0.80
Impact of secretome containing extracellular vesicles from human induced pluripotent stem cell-derived cardiomyocytes.
FindingNot reported in abstract.
In vitro2026Full text read0.80
Metabolic engineering of <i>Escherichia coli</i> based on adaptive evolution and omics technology for highly efficient l-valine production under oxygen-limited conditions.
Findingl-valine titer of 93.7 g/L within 28 h in a 5-L bioreactor.
In vitro2026Full text read0.80
Identification of integration site library for the development of plasmid-free microbial cell factory in <i>Bacillus subtilis</i>.
FindingThe highest expression site spxA was 1.89 times as high as amyE.
In vitro2026Full text read0.70
Quorum sensing-driven riboflavin-hyperproducing electroactive bacteria for enhanced bioelectricity generation from sludge: From modular optimization to process performance.
Finding269.9 mg/L riboflavin produced under bioreactor conditions.
In vitro2026Full text read0.80
scYeast: a biological-knowledge-guided foundation model on yeast single-cell transcriptomics.
TakeawayscYeast is a promising tool for advancing yeast single-cell biology by integrating biological priors into foundational models.
review2026Full text read0.70
CodY constrains β-cypermethrin degradation by regulating physiological adaptation and soil ecological performance in <i>Bacillus cereus</i> GW-01.
Findingβ-cypermethrin half-life reduced from 3.61–12.62 d to 2.42–9.61 d in ΔcodY.
In vitro2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Sermorelin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Sermorelin is discussed should be drawn from it.

Articles mentioning Sermorelin